Browse studies

Find your next paid study

158 recruiting studies matching your filters

Mitochondrial Encephalomyopathies and Mental Retardation: Investigations of Clinical Syndromes Associated With MtDNA Point Mutations

Carriers of the m.3242A\>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal…

MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier

Estimated

~$10 – $750

Columbia UniversityNCT01532791

Natural History Study for the ASXL-Related Disorders and Chromatinopathies

A registry focused on the natural history, management and treatment of patients with Bohring-Opitz Syndrome (ASXL1), Shashi-Pena Syndrome (ASXL2) and Bainbridg…

Bohring-Opitz SyndromeASXL1 Gene MutationShashi-Pena Syndrome+3 more

Estimated

~$10 – $750

University of California, Los AngelesNCT03303716

Phase 2

Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for c…

Hematologic MalignancyAcute LeukemiaRemission+21 more

Estimated

~$10 – $6,250

Masonic Cancer Center, University of Minnesota

Phase 1

An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of ANS014004 in Combination With EGFR-TKI in Patients With EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Protocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cel…

Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more

Estimated

~$10 – $8,750

Beijing Pearl Biotechnology Limited Liability CompanyNCT07285148

Phase 3

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be re…

Pancreas CancerPeutz-Jeghers Syndrome (PJS)Gene Mutation+2 more

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT02000089

Congenital Muscle Disease Patient and Proxy Reported Outcome Study

The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a longitudinal 10 year study to identify and trend care parameters, adverse…

Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) DeficiencyAlpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)+49 more

Observational

A Prospective, Randomized Trial to Compare Telegenetics to Counseling Via a Novel Genetic Information Assistant in High-risk Cancer Patients.

The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for…

Gene Mutation-Related CancerGenetic Predisposition

Estimated

~$10 – $6,250

University of VirginiaNCT06089421

Phase 2

A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas

This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradia…

Salivary Gland CancerHER2 Gene Mutation

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT04620187

Phase 2

A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors

The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPN…

Wilms TumorRhabdoid TumorMalignant Peripheral Nerve Sheath Tumors+4 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05985161

Phase 1

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBC+2 more

Estimated

~$10 – $8,750

Jacobio Pharmaceuticals Co., Ltd.NCT05490472

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer …

Uveal MelanomaCutaneous MelanomaBAP1 Gene Mutation+5 more

Estimated

~$10 – $1,125

Mohamed Abdel-RahmanNCT04792463

Phase 1

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients

Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients

Acute Myeloid LeukemiaTP53 Gene Mutation

Estimated

~$10 – $6,250

Northside Hospital, Inc.NCT07511062